WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research
OverviewZen RatingPriceValueGrowthFinancialsMomentumSentimentForecast
DividendsDue Diligence
B
Diagnostics & Research is Zen Rated B and is the 43rd ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Market Cap
Price
Price Target
Upside/Downside
Top Analysts Upside/Downside
Consensus
Top Analysts Consensus
Analysts
Top Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
ILMN
ILLUMINA INC
$20.29B$132.72$138.604.43%Buy106.07%7.19%42.73%17.51%
SHC
SOTERA HEALTH CO
$4.50B$15.83$21.0032.66%Strong Buy56.50%62.72%61.14%11.35%
TMO
THERMO FISHER SCIENTIFIC INC
$191.69B$516.00$653.6926.68%Strong Buy135.97%18.84%23.27%11.26%
BLLN
BILLIONTOONE INC
$3.62B$78.82$126.7160.76%Strong Buy737.89%140.22%16.46%12.49%
IQV
IQVIA HOLDINGS INC
$29.18B$171.95$230.5434.07%Strong Buy136.21%25.99%45.49%9.88%
MTD
METTLER TOLEDO INTERNATIONAL INC
$26.24B$1,290.84$1.51k16.93%Buy85.34%10.67%-5,525.14%35.17%
BNR
BURNING ROCK BIOTECH LTD
$235.73M$22.50N/AN/AN/AN/AN/AN/AN/AN/A
A
AGILENT TECHNOLOGIES INC
$33.42B$118.25$164.3338.97%Strong Buy125.96%17.82%33.38%18.00%
NTRA
NATERA INC
$27.79B$196.11$259.3932.27%Strong Buy1318.72%N/A15.01%10.72%
PRPO
PRECIPIO INC
$51.73M$29.00N/AN/AN/AN/AN/AN/AN/AN/A
MEDP
MEDPACE HOLDINGS INC
$14.63B$515.65$535.003.75%Buy89.97%11.36%147.20%34.21%
DHR
DANAHER CORP
$137.03B$193.78$251.8829.98%Strong Buy85.91%25.88%15.27%9.61%
CAI
CARIS LIFE SCIENCES INC
$5.76B$20.40$27.8336.44%Buy621.52%N/A35.59%18.26%
IDXX
IDEXX LABORATORIES INC
$45.38B$569.95$748.1331.26%Strong Buy89.47%12.80%103.96%49.81%
CDNA
CAREDX INC
$1.15B$22.42$23.504.82%Buy213.59%N/A27.96%20.51%
LH
LABCORP HOLDINGS INC
$21.95B$266.36$316.0018.64%Buy65.98%26.88%22.45%10.52%
NEOG
NEOGEN CORP
$2.01B$9.24$10.6715.44%Buy30.12%N/A4.86%3.04%
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$8.71B$176.94$200.4413.28%Buy92.00%N/A22.44%9.95%
RVTY
REVVITY INC
$10.01B$89.53$107.8920.51%Buy95.66%47.50%11.56%6.89%
BDSX
BIODESIX INC
$131.21M$13.31$20.0050.26%Strong Buy122.42%N/AN/A-15.29%
DGX
QUEST DIAGNOSTICS INC
$21.04B$191.46$216.1112.88%Buy95.20%12.39%21.90%9.68%
MYGN
MYRIAD GENETICS INC
$467.54M$5.00$7.3847.50%Buy45.79%N/A15.46%8.05%
NEO
NEOGENOMICS INC
$1.06B$8.16$14.0071.57%Strong Buy29.80%N/A9.72%5.98%
WAT
WATERS CORP
$31.30B$319.04$386.8221.24%Buy1133.19%19.36%77.66%39.18%
CSTL
CASTLE BIOSCIENCES INC
$730.20M$24.56$48.6097.88%Strong Buy58.43%N/A3.64%2.96%
ICLR
ICON PLC
$8.83B$115.58$141.1722.14%Buy63.84%30.06%12.73%7.20%
QGEN
QIAGEN NV
$8.89B$40.96$52.6028.42%Buy56.60%17.34%19.56%11.77%
QUCY
MAINZ BIOMED NV
$6.31M$0.50N/AN/AN/AN/A265.99%N/AN/AN/A
TWST
TWIST BIOSCIENCE CORP
$3.45B$56.23$50.00-11.08%Strong Buy514.82%N/AN/AN/A
RDNT
RADNET INC
$4.66B$60.09$88.7547.70%Strong Buy416.91%N/A8.57%2.49%
LAB
STANDARD BIOTOOLS INC
$360.43M$0.92$1.3546.10%Hold1-0.24%N/A-8.45%-6.31%
BIAF
BIOAFFINITY TECHNOLOGIES INC
$12.42M$2.76N/AN/AN/AN/AN/AN/A-510.71%-339.10%
PRE
PRENETICS GLOBAL LTD
$287.66M$17.94$30.5070.01%Strong Buy2108.69%N/A-2.97%-2.55%
PSNL
PERSONALIS INC
$696.85M$6.66$12.2083.18%Buy531.18%N/A-5.31%-4.15%
STIM
NEURONETICS INC
$95.88M$1.40$3.00114.29%Strong Buy112.86%N/AN/AN/A
MDXH
MDXHEALTH SA
$11.30M$2.20$7.67248.50%Strong Buy322.13%N/AN/AN/A
GH
GUARDANT HEALTH INC
$11.24B$85.70$129.6951.33%Strong Buy1628.96%N/A-344.65%17.00%
OPK
OPKO HEALTH INC
$928.92M$1.21$1.5528.10%Buy20.25%N/AN/AN/A
XWEL
XWELL INC
$8.24M$1.04N/AN/AN/AN/AN/AN/AN/AN/A
XGN
EXAGEN INC
$73.36M$3.05$9.50211.48%Strong Buy610.83%N/A37.59%11.30%
FLGT
FULGENT GENETICS INC
$503.75M$16.13$30.0085.99%Hold111.18%N/A-4.13%-3.78%
GRAL
GRAIL INC
$1.93B$49.47$68.1737.79%Buy626.59%N/A-11.51%-10.15%
ACRS
ACLARIS THERAPEUTICS INC
$431.21M$3.98$11.33184.75%Buy3-12.94%N/A-93.99%-60.38%
IMDX
INSIGHT MOLECULAR DIAGNOSTICS INC
$112.91M$3.51$10.50199.15%Strong Buy2-35.22%N/AN/A-110.44%
SERA
SERA PROGNOSTICS INC
$91.99M$2.35N/AN/AN/AN/A390.54%N/A-21.71%-16.06%
NOTV
INOTIV INC
$10.15M$0.30$1.50408.47%Strong Buy116.45%N/AN/AN/A
DRIO
DARIOHEALTH CORP
$51.32M$7.03$10.0042.25%Strong Buy134.64%N/A12.06%7.44%
MBAI
CHECK-CAP LTD
$282.65M$1.86N/AN/AN/AN/AN/AN/AN/AN/A
BNBX
BNB PLUS CORP
$3.14M$0.58N/AN/AN/AN/AN/AN/A-2,433.68%-2,214.83%
ISPC
ISPECIMEN INC
$3.47M$0.12N/AN/AN/AN/AN/AN/AN/AN/A
ADVB
ADVANCED BIOMED INC
$5.16M$4.77N/AN/AN/AN/AN/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$12.91M$0.70N/AN/AN/AN/AN/AN/AN/A-185.27%
NDRA
ENDRA LIFE SCIENCES INC
$6.41M$5.17$30.00480.27%Buy1N/AN/AN/AN/A
VNRX
VOLITIONRX LTD
$27.89M$0.18$1.67847.16%Strong Buy3280.19%N/A-292.65%1,452.26%
FONR
FONAR CORP
$122.98M$18.76N/AN/AN/AN/AN/AN/AN/AN/A
1

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Illumina (NASDAQ:ILMN)


Illumina (NASDAQ:ILMN) is the #1 top diagnostic & research stock out of 55 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: A, and AI: B.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 37, which is 9 points higher than the diagnostic & research industry average of 28.

ILMN passed 12 out of 33 due diligence checks and has average fundamentals. Illumina has seen its stock return 80.5% over the past year, overperforming other diagnostic & research stocks by 55 percentage points.

Illumina has an average 1 year price target of $138.60, an upside of 4.43% from Illumina's current stock price of $132.72.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 33, which is 5 points higher than the diagnostic & research industry average of 28.

SHC passed 11 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 50.91% over the past year, overperforming other diagnostic & research stocks by 25 percentage points.

Sotera Health Co has an average 1 year price target of $21.00, an upside of 32.66% from Sotera Health Co's current stock price of $15.83.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Sotera Health Co, 60% have issued a Strong Buy rating, 20% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Thermo Fisher Scientific (NYSE:TMO)


Thermo Fisher Scientific (NYSE:TMO) is the #3 top diagnostic & research stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Thermo Fisher Scientific (NYSE:TMO) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: C, and AI: B.

Thermo Fisher Scientific (NYSE:TMO) has a Due Diligence Score of 37, which is 9 points higher than the diagnostic & research industry average of 28.

TMO passed 13 out of 38 due diligence checks and has average fundamentals. Thermo Fisher Scientific has seen its stock return 18.13% over the past year, underperforming other diagnostic & research stocks by -7 percentage points.

Thermo Fisher Scientific has an average 1 year price target of $653.69, an upside of 26.68% from Thermo Fisher Scientific's current stock price of $516.00.

Thermo Fisher Scientific stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Thermo Fisher Scientific, 76.92% have issued a Strong Buy rating, 15.38% have issued a Buy, 7.69% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.7%, which is 1 percentage points higher than the diagnostic & research industry average of 0.82%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.1% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)


Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.08%, which is the same as the diagnostic & research industry average of 0.82%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 27.3% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) has an annual dividend yield of 0.85%, which is the same as the diagnostic & research industry average of 0.82%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.62% in the last day, and up 0.03% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 100, which is 85 points higher than the diagnostic & research industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Icon's stock has dropped -19.48% in the past year. It has underperformed other stocks in the diagnostic & research industry by -45 percentage points.

2. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 43, which is 28 points higher than the diagnostic & research industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Qiagen Nv's stock has dropped -1.16% in the past year. It has underperformed other stocks in the diagnostic & research industry by -27 percentage points.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Agilent Technologies has a valuation score of 14, which is -1 points higher than the diagnostic & research industry average of 15. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates A a Valuation Rating of "B".

Agilent Technologies's stock has gained 15.14% in the past year. It has underperformed other stocks in the diagnostic & research industry by -10 percentage points.

Are diagnostic & research stocks a good buy now?

51.16% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 23.69% over the next year.

2.27% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 27.27% of diagnostic & research stocks are rated B (Buy), 54.55% are rated C (Hold), 15.91% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 21.61x.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.